Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Molina, J.
Right arrow Articles by Urbina, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molina, J.
Right arrow Articles by Urbina, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 137-140
© 2000 The British Society for Antimicrobial Chemotherapy

Brief reports

In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi

Judith Molinaa,b, Zigman Brenerb, Alvaro J. Romanhac and Julio A. Urbinad,*

a Departmento de Parasitología, Instituto de Zoología Tropical, Universidad Central de Venezuela, Caracas 1041, Venezuela; b Laboratorio de Doença de Chagas and c Laboratorio de Parasitologia Celular e Molecular, Centro de Pesquisas Rene Rachou, Fundaçao Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil; d Laboratorio de Química Biológica, Centro de Biofísica y Bioquímica, Instituto Venezolano de Investigaciones Científicas, Apartado 21827, Caracas 1020A, Venezuela

We report the in vivo activity of the bis-triazole derivative D0870 against a variety of strains of Trypanosoma cruzi, the causative agent of Chagas' disease, including nitroimidazole/nitrofuran-resistant strains. In both acute and chronic murine models of the disease, treatment with D0870 at <= 10 mg/kg on alternate days for a total of 20 doses provided 60–100% protection against death, regardless of the drug sensitivity of the infecting strain. In the acute model we obtained 70–100% parasitological cure in seven of the nine strains tested, including one intermediate and two highly drug-resistant strains. D0870 was able to cure 30–45% of animals chronically infected with various strains, including those harbouring the Colombiana strain, among which no cures were obtained with benznidazole. We also found that the anti-T. cruzi activity of D0870 is largely retained even if the hosts are immunosuppressed.

* Corresponding author. Tel: +58-2-5041479; Fax: +58-2-5041093; E-mail: jaurbina{at}cbb.ivic.ve


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. L. Ferraz, R. T. Gazzinelli, R. O. Alves, J. A. Urbina, and A. J. Romanha
Absence of CD4+ T Lymphocytes, CD8+ T Lymphocytes, or B Lymphocytes Has Different Effects on the Efficacy of Posaconazole and Benznidazole in Treatment of Experimental Acute Trypanosoma cruzi Infection
Antimicrob. Agents Chemother., January 1, 2009; 53(1): 174 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. J. d. O. Toledo, M. T. Bahia, C. M. Carneiro, O. A. Martins-Filho, M. Tibayrenc, C. Barnabe, W. L. Tafuri, and M. de Lana
Chemotherapy with Benznidazole and Itraconazole for Mice Infected with Different Trypanosoma cruzi Clonal Genotypes
Antimicrob. Agents Chemother., January 1, 2003; 47(1): 223 - 230.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
K. J. Williams and D. W. Denning
Termination of development of D0870
J. Antimicrob. Chemother., May 1, 2001; 47(5): 720 - 721.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Molina, J. Urbina, R. Gref, Z. Brener, and J. M. Rodrigues Junior
Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres
J. Antimicrob. Chemother., January 1, 2001; 47(1): 101 - 104.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.